Connect with us
DAPA Banner

Business

Will BTC Keep Plunging Below $65K? Expert Predictions for February 2026 Recovery

Published

on

Bitcoin Price Crash: Will BTC Keep Plunging Below $65K? Expert

Bitcoin has tumbled to its lowest levels since last fall, briefly dipping below $61,000 this week before rebounding slightly to around $64,800 amid a brutal sell-off that has wiped out nearly 50% of its value from October highs. The world’s largest cryptocurrency by market cap — now hovering at $1.29 trillion — faces mounting questions: Is this the bottom, or will BTC keep going down as investor panic deepens?

The dramatic plunge, down 32% over the past 12 months and 44% from its $126,296 peak, has triggered widespread deleveraging, ETF outflows and skepticism about crypto’s post-election rally. Yet historical patterns, improving macro signals and technical rebounds suggest the bleeding may soon stop — though analysts warn of more pain before any sustained recovery.

Bitcoin’s brutal week: From $92K dreams to $60K reality

Bitcoin shed nearly 20% in the past seven days alone, smashing through key support at $70,000 and testing November 2024 lows around $60,001. Thursday’s session saw BTC briefly crater below $61,000 — its steepest single-day drop in months — fueled by $3.48 billion in spot ETF outflows since November and liquidations hitting overcrowded long positions.

Major platforms like Bitstamp clocked lows of $70,002 early Thursday, while Coinbase watched BTC flirt with $60K amid risk-off sentiment spilling from stocks. Ether and XRP suffered worse, amplifying the crypto bloodbath as traditional investors soured on digital assets.

Advertisement

Deutsche Bank’s Marion Laboure pinned the rout on fading hype: “Traditional investors are losing interest… Bitcoin isn’t trading on narratives anymore; it’s pure liquidity dynamics.” FG Nexus’s Aja Vinovic added that post-ETF euphoria has given way to balance-sheet pressures, with put options now outpacing calls.​

Why Bitcoin is crashing now: ETF flows, macro headwinds

Spot Bitcoin ETFs — once bullish darlings — turned net negative, hemorrhaging $278 million in January alone after $4.57 billion in late-2025 outflows. BlackRock’s IBIT led the exodus, signaling institutional profit-taking after BTC’s 2025 surge.

Macro jitters amplified the slide. Fed hawkishness crushed rate-cut bets, strengthening the dollar and squeezing risk assets. Bitcoin’s correlation with Nasdaq hit 0.85, dragging BTC down as tech stocks wobbled. On-chain data shows new buyer activity stalled since October, with sentiment nearing fear extremes — historically bullish contrarian signals.

Technicals scream oversold: Wedge pattern eyes rebound

Charts paint a mixed but intriguing picture. Bitcoin trades inside an ascending broadening wedge, bouncing from the lower boundary near $60K — a classic reversal setup. Bulls must reclaim $89,241 and $90,000 for bullish confirmation; failure risks $55K tests.

Advertisement

The 50-day moving average sits at $87,974, with the 200-day at $103,031 — both far above spot price, underscoring the correction’s depth. Yet RSI readings below 30 signal extreme oversold conditions, while February’s historical 14.3% average gains favor upside.

Changelly forecasts BTC climbing to $77,862 by month-end (20% from here), with short-term targets at $71,840 Friday and $77K late February. BeInCrypto eyes $98K on wedge breakout, followed by $95K consolidation.

Historical precedent: 30% drops are BTC’s normal

Pullbacks of 30%+ are routine in Bitcoin cycles. Post-2021 and 2017 peaks, BTC endured multiple 30-50% corrections before resuming uptrends. The current 44% retracement mirrors March 2025’s 32.7% dip and January’s 31.7% slide — “normal volatility,” per CoinDesk’s Jacob Joseph.​

Santiment data confirms: Extreme fear precedes bounces, with current caution levels priming gradual advances. ETF outflow slowdown — from $3.48B (Nov) to $278M (Jan) — hints at stabilization.

Advertisement

Bull case: ETF rebound, halving tailwinds, macro pivot

Optimists see catalysts ahead. Spot ETF flows could flip positive in February, providing “structural support.” The 2024 halving’s supply shock lingers, with 3.125 BTC block rewards tightening issuance amid rising demand.​

Macro tailwinds beckon: Potential Fed cuts, election-cycle liquidity and Trump’s pro-crypto stance (Bitcoin reserve talk) could ignite FOMO. On-chain metrics show long-term holders accumulating, HODL waves strengthening.​

Price targets cluster at $90K (near-term resistance), $101K (14% historical February gain) and $126K year-high retest.

Bear case: $55K floor, recession risks loom

Pessimists warn of deeper pain. Failure at $70K invites $55K — 2024 lows — with $44K psychological support. Persistent ETF selling, regulatory clouds (SEC vs. Ripple redux?) and equity contagion threaten further slides.​

Advertisement

Deutsche Bank’s Laboure flags “overall negativity” as traditional capital flees. If Nasdaq cracks, BTC’s 0.85 correlation amplifies downside.​

Expert predictions: Where BTC heads next

Analyst/Firm Short-Term (Feb) Year-End 2026 Key Catalyst
BeInCrypto $98K breakout $120K+ ETF inflows ​
Changelly $77.8K $95K avg Technical rebound ​
CoinDesk Stabilize $80K Cycle peak Halving effects ​
Deutsche Bank $60K risk Bearish Macro caution ​

February averages 14.3% gains historically; current $64.8K base projects $74K end-month.​

What Bitcoin investors should do now

  1. HODL long-term: Corrections precede bull runs; 2021’s 50% drop yielded 3x gains.​
  2. Dollar-cost average: Buy dips below $65K; avoid FOMO at $90K.​
  3. Watch ETF flows: Inflow reversal signals bottom.​
  4. Monitor Fed: Rate cuts ignite risk-on.​
  5. Risk management: Never invest more than 5-10% portfolio.​

Bitcoin’s at a crossroads: capitulation or coil for explosion? History favors the latter, but patience rules. As Vinovic notes, “The bull run narrative evolves — liquidity now drives price.” Tune into macro prints, ETF data and $70K hold for clues. The king of crypto endures — battered, but unbowed.

Continue Reading
Click to comment

You must be logged in to post a comment Login

Leave a Reply

Business

(VIDEO) Tiger Woods Had Hydrocodone Pills in Pocket During Florida DUI Rollover Crash, Affidavit Reveals

Published

on

Golfing superstar Tiger Woods spent his second full day recovering from a car crash at Los Angeles Cedars-Sinai hospital which is known for treating wealthy celebrities

Golf legend Tiger Woods was found with two loose hydrocodone pills — a prescription opioid — in his left pants pocket after a single-vehicle rollover crash that led to his arrest on suspicion of driving under the influence last Friday, according to a probable cause affidavit released Tuesday by Martin County authorities.

Golfing superstar Tiger Woods spent his second full day recovering from a car crash at Los Angeles Cedars-Sinai hospital which is known for treating wealthy celebrities
GETTY IMAGES NORTH AMERICA / ANDY LYONS

The new details, first reported by TMZ Sports and confirmed across multiple outlets, paint a fuller picture of the March 27 incident on a residential road in the affluent Jupiter Island community. Woods, 50, told deputies he was distracted by his cellphone and changing the radio station moments before his luxury Land Rover struck the rear of a work truck and flipped onto its side. No one was seriously injured, but the crash has reignited questions about the 15-time major champion’s ongoing battles with pain management, prescription medications and road safety.

Deputies described Woods as profusely sweating despite cool air in the vehicle, moving in a “lethargic and slow” manner, and showing “severe signs of impairment.” When he removed his sunglasses, officers noted his eyes were “bloodshot and glassy” with “extremely dilated” pupils. A breathalyzer test registered 0.00 for alcohol, but Woods refused a urine test under Florida’s strengthened implied consent law for suspected drug impairment, leading to an additional charge.

During a search incident to arrest, deputies discovered two white pills marked “M367” in Woods’ pocket. The imprint identified them as hydrocodone, an opioid commonly prescribed for severe or chronic pain. Woods acknowledged taking “a few” prescription medications earlier that morning when asked by investigators. The pills were seized and entered into evidence.

Advertisement

The affidavit adds to the narrative of a golfer whose body has endured years of punishing physical tolls from elite competition and multiple surgeries, including multiple back operations and a 2021 car crash in California that left him with severe leg injuries. Woods has been open in the past about relying on pain medication during recovery periods, but the presence of loose opioids during a driving incident has drawn sharp scrutiny.

Martin County Sheriff John Budensiek said at a news conference last week that investigators believed Woods was impaired by “some type of medication or drug” rather than alcohol. Woods was booked on misdemeanor charges of DUI with property damage and refusal to submit to a lawful test. He was released from jail overnight Friday after posting bond and has not yet entered a plea.

The crash occurred around 2 p.m. as Woods reportedly attempted to pass a pressure cleaner truck on a road with a 30 mph speed limit. He crawled out of the overturned vehicle through a window and was seen on his phone near the wreckage. Photos from the scene showed the Land Rover resting on its side with visible damage.

This marks Woods’ second high-profile DUI-related incident. In 2017, he was arrested in Florida after being found asleep at the wheel of his Mercedes. Toxicology reports at the time revealed five substances in his system, including the opioid hydrocodone (Vicodin), hydromorphone (Dilaudid), Xanax, Ambien and THC. Woods later pleaded guilty to reckless driving and completed a program addressing his issues with prescription medications.

Advertisement

Tuesday’s affidavit has prompted fresh discussion about prescription opioid use among athletes managing chronic pain. Hydrocodone is a Schedule II controlled substance with high potential for dependence. Medical experts note that while it can be legitimately prescribed, combining it with other medications or using it while driving can significantly impair judgment, reaction time and coordination.

Woods has been attempting a cautious comeback in 2026 after years of limited competitive play due to injuries. He participated in the TGL Finals earlier in the week, a tech-infused golf league event, and had expressed hope of competing at the Masters Tournament, which begins April 9 in Augusta, Georgia. His representatives have not commented publicly on the latest developments or his plans for the storied event, where he has won five green jackets.

PGA Tour officials and fellow players have offered measured responses, emphasizing support for Woods’ health while noting the seriousness of impaired driving. Some teammates in the TGL expressed concern over what one called “disturbing” recent events.

The incident also revives memories of Woods’ 2021 rollover crash in Rancho Palos Verdes, California, where his SUV veered off a winding road at high speed. He suffered compound fractures in his right leg and underwent extensive rehabilitation. An empty pill bottle was reportedly found in that vehicle, though no charges were filed related to impairment.

Advertisement

Legal analysts say the current case could hinge on field sobriety test performance, the deputy’s observations of impairment, the refused urine test and any eventual toxicology results if pursued. Under Florida law, refusal to submit to testing after a DUI arrest can lead to automatic license suspension and may be used as evidence in court.

Woods owns multiple properties in the Jupiter area, including a waterfront estate, and has deep ties to South Florida’s golf community. He has largely kept a low profile off the course in recent years, focusing on his children, business ventures such as his golf course design firm and the TGL league he co-founded with Rory McIlroy.

Public reaction on social media has been swift and divided. Some fans expressed disappointment and concern for Woods’ well-being, while others highlighted the potential dangers of driving while impaired by any substance. The story dominated sports headlines Tuesday, with the new affidavit details amplifying coverage of the Friday crash.

As of Tuesday afternoon, no court date had been set. Woods remains eligible to travel and compete pending resolution of the charges, though any conviction could carry consequences for his driving privileges and public image.

Advertisement

The golf world will watch closely how Woods navigates this latest chapter. His resilience through physical adversity has been well-documented, but repeated incidents involving driving and medications raise questions about long-term management of his health and lifestyle.

Martin County authorities have not released bodycam or dashcam footage, citing the ongoing investigation. The second driver involved in the crash was not injured and cooperated with investigators.

For a figure who transcended golf to become one of the most recognizable athletes globally, Tuesday’s revelations add another complex layer to a career marked by triumph, scandal, injury and remarkable comebacks. Whether this proves a minor legal hurdle or a more significant turning point remains to be seen as the legal process unfolds.

Woods’ team has historically emphasized privacy around medical matters. In past statements, he has credited surgery, physical therapy and mental focus for his recoveries while acknowledging the cumulative wear on his body from decades at the highest level of professional golf.

Advertisement

As spring arrives and the golf season intensifies toward the Masters, the focus for many will shift from Woods’ past glories to his present challenges — both on and off the course. Supporters hope for transparency, accountability and continued progress in addressing any underlying issues with pain and medication.

Continue Reading

Business

At Close of Business podcast March 31 2026

Published

on

At Close of Business podcast March 31 2026

Isabel Vieira and Mark Pownall discuss a restructure with WA’s biggest wine maker Fogarty Wine Group.

Continue Reading

Business

Apartments planned above resort’s iconic former Woolworths store

Published

on

Apartments planned above resort’s iconic former Woolworths store


Amendments made to project at Art Deco landmark

Continue Reading

Business

Perth family law firm Paterson & Dowding wins injunction to protect stolen data

Published

on

Perth family law firm Paterson & Dowding wins injunction to protect stolen data

A boutique Perth family law firm has been granted an injunction over data stolen during a recent cyber attack, preventing it from being accessed and shared by Australian outlets or companies.

Continue Reading

Business

US petrol price tops $4 for first time since 2022

Published

on

US petrol price tops $4 for first time since 2022

The Iran war continues to push up prices at the pump for US motorists.

Continue Reading

Business

Novo Nordisk launches Wegovy subscription for GLP-1 obesity drugs

Published

on

Wegovy semaglutide tablets.

Michael Siluk | Universal Images Group | Getty Images

Novo Nordisk on Tuesday launched a multi-month subscription program for its Wegovy obesity drug products that aims to ensure cash-paying patients see lower, “predictable” monthly prices. 

Advertisement

Eligible patients can choose between three-, six- or 12-month subscriptions for the Wegovy injection or the two highest doses of the newly launched pill under the same brand name. Longer plans offer lower monthly pricing, and the company expects people to save up to $1,200 a year on the injection and as much as $600 a year on the pill, relative to paying for their individual dose each month, according to a Novo release. 

Patients can expect to pay flat monthly prices, even if they move to different doses, the company said. The subscription program will be available starting Tuesday on several of Novo’s telehealth partners, including Ro, WeightWatchers, LifeMD, Sesame and Hims & Hers, with more expected to be added soon. 

The first-of-its-kind offering is “an opportunity to help patients not only start but stay on therapy and help them manage the ups and downs of some of the pricing considerations,” regardless if they are starting treatment or are currently taking the drug, said Ed Cinca, Novo’s head of marketing and patient solutions. 

Inability to stay on GLP-1s is a longstanding issue due to factors such as difficulty accessing the drugs and gastrointestinal side effects, with one 2025 study estimating that around 65% of patients with obesity stop treatment within a year. 

Advertisement

Wegovy subscription prices and estimated savings

Injection subscription plans (0.25, 0.5, 1.7 and 2.4 milligram doses)

  • 3-month: $329 per month, savings of $240 per year
  • 6-month: $299 per month, savings of $600 per year
  • 12-month: $249 per month, savings of $1,200 per year

Pill subscription plans (9 and 25 milligram doses) 

  • 3-month: $289 per month, savings of $120 per year
  • 6-month: $269 per month, savings of $360 per year
  • 12-month: $249 per month, savings of $600 per year

The new program also comes as Novo’s pill, which has seen explosive uptake since its U.S. launch in January, is set to face fresh competition from an upcoming oral GLP-1 from chief rival Eli Lilly later this year. Lilly is currently the dominant player in the branded GLP-1 market in the U.S., with an estimated 60% share, while Novo has about 39%.

The Wegovy pill has largely been reaching people who didn’t previously take GLP-1 injections, making it crucial for Novo to capture as many new patients as it can before a competitor arrives. 

As Novo Nordisk’s subscription plans launch, cash-paying patients can still pay $149 per month for the lower doses of the pill, which are 1.5 and 4 milligrams. But starting in August, the 4-milligram dose will cost $199 per month. Meanwhile, the recently approved 7.2-milligram dose of Wegovy will be added to the subscription program at a later date. 

Advertisement

Cinca emphasized that patients can opt out of the subscription while it’s active if they no longer wish to enroll.

“We want to help patients identify a path that can help them feel comfortable about treating [obesity] in the long term,” he added.

Cinca said Novo is not yet offering the program on its NovoCare direct-to-consumer pharmacy, but added that there’s “an opportunity to evaluate how this goes and then build it out” through that platform over time. 

Choose CNBC as your preferred source on Google and never miss a moment from the most trusted name in business news.
Advertisement
Continue Reading

Business

Bulls to return after March massacre? Elara sees limited downside for Nifty after 11% crash amid Iran-US war

Published

on

The raging war in the oil-rich Middle East has rattled stock markets across the globe, with Dalal Street being no exception. After crashing more than 11% in March, Elara Securities said that historical patterns suggest limited downside for the benchmark index Nifty.

The domestic brokerage cited data from the timeframes of seven major geopolitical conflicts in the past 25 years – Iraq war (2003), the Lebanon war (2006), the Libyan Civil War (2011), Russia–Ukraine (2022), Israel–Hamas war (2023), Iran–Israel conflict (2025), and the ongoing US–Iran escalation. It said that Nifty’s drawdown during the onset of conflicts has usually been capped at approximately 10%. Hence, historical patterns suggest limited downside for the benchmark index now, after the 11% crash in March.

“Importantly, once early signs of normalisation emerge, markets tend to recover swiftly,” Elara said. However, it noted that the key exception to this historical pattern was in calendar years 2011-2014 when Brent sustained above $100 per barrel, leading to a prolonged sideways market without meaningful highs. The eventual decline in oil prices acted as the trigger for a strong Nifty upcycle, it added.

Also read: Sammaan Capital becomes IHC Group co, receives Rs 5,652 cr in first tranche of stake sale

Advertisement

Nifty’s valuation below the long-term trend signals a potential rebound

Elara assessed the one-year forward P/E relative to its rolling 10-year average and concluded the Nifty is trading 7% below its 10-year average, placing it in a historical “bounce zone”. “Outside of extreme disruptions like COVID-19, this level usually acted as a floor for valuation. Even during the Russia–Ukraine conflict, despite Brent sustaining above USD 100/bbl, Nifty multiples bounced back from 10-year rolling averages,” it said.

“The recent TACO and Iran allowing ‘nonhostile ships’ to transit the Strait of Hormuz, along with crude oil prices dropping below USD 100/bbl, have reduced immediate energy supply risks. With our base case assuming gradual de-escalation, the current valuation provides a favourable entry point, with limited downside. We pick 20 value plays which offer a good risk-reward opportunity with healthy fundamentals in the current scenario of extreme correction,” the brokerage added.

Elara’s top pics

Auto and power remain Elara’s preferred bets, which added that large-cap auto stocks like Maruti Suzuki and Royal Enfield-maker Eicher Motors have corrected sharply since the onset of the US-Iran conflict. While near-term concerns persist around input cost pressures from elevated commodity prices and potential demand moderation in the event of a prolonged conflict triggering an inflation shock for consumers, underlying retail data remains robust and encouraging, it further said.
The domestic brokerage added that Vahan retail registrations so far show strong double-digit growth, and this momentum is expected to receive further tailwinds from the Eighth Pay Commission awards, slated for announcement early next year.Within the power sector, 18 out of the 19 utility stocks under the brokerage’s coverage have outperformed the Nifty 50 in current drawdown, which the firm said underscores the sector’s relative resilience. “The escalating conflict is expected to accelerate India’s electrification cycle, while surging data centre capex is driving incremental power demand. This positive backdrop is further supported by the likely passage of the New Electricity Amendment Bill, which will unlock structural reforms in the sector. Consequently, power generation, transmission, distribution, and data centre-linked plays are emerging not merely as defensive anchors but as clear structural beneficiaries in the medium to long term. NTPC, NLC India, and ACME Solar remain our highest conviction picks within the space,” it added.

Also read: FY26 IPO market a disaster as investors lose money in 2 out of 3 issues. Will next year be better?

Where is the value currently?

In its report, Elara listed out several stocks emerging with better risk-reward dynamics where fundamentals remain intact, and valuation is either trading below the five-year median, and in some cases even below the Russia–Ukraine crisis lows.

Advertisement

These include HDFC Bank, Maruti Suzuki, Eicher Motors, Infosys, LTI Mindtree, L&T, Godrej Properties, NTPC, NLC India, ACME Solar and Eternal.

(Disclaimer: Recommendations, suggestions, views and opinions given by the experts are their own. These do not represent the views of The Economic Times)

Continue Reading

Business

The Quiet Rituals of Self-Respect: How Everyday Products Shape the Way You Treat Yourself

Published

on

The Quiet Rituals of Self-Respect: How Everyday Products Shape the Way You Treat Yourself

There’s a subtle difference between self-care and self-respect.

Self-care is often portrayed as something occasional—spa days, special routines, moments carved out for relaxation. It’s visible, sometimes even performative.

Self-respect, on the other hand, is quieter. It lives in the decisions you make when no one is watching. It shows up in consistency, in the standards you set for yourself, and in the way you engage with your daily routines.

And perhaps surprisingly, it’s often reflected in the most ordinary products you use.

Advertisement

The Standard You Accept

Every product you use sets a baseline.

Not just for performance, but for what you consider “good enough.”

If something works “well enough,” you keep using it. If it causes minor irritation or discomfort, you might ignore it. Over time, these small compromises become normalized.

This is how standards quietly drift.

Advertisement

But when you choose something like aluminum and baking soda free deodorant, you’re making a different kind of decision. You’re saying that “good enough” isn’t enough—that your comfort, your skin, and your long-term well-being matter.

It’s not a dramatic statement. It’s a quiet adjustment in standards.

The Daily Mirror

Your routine is a mirror.

Not in the literal sense, but in what it reflects back to you about how you treat yourself.

Advertisement

Do you rush through it, using whatever is easiest?
Do you pay attention to how things feel?
Do you notice when something isn’t working for you?

These questions aren’t about perfection. They’re about awareness.

Using an organic face soap, for example, can shift your experience from purely functional to slightly more intentional. The ingredients, the texture, the way it interacts with your skin—all of it becomes part of a more attentive process.

You’re not just washing your face. You’re engaging with the act.

Advertisement

And that engagement reflects a form of respect.

The Relationship You Have with Routine

Most routines are built on autopilot.

You wake up, go through the motions, and move on. Efficiency takes priority over experience.

But routines are also opportunities.

Advertisement

They’re moments that repeat every day, giving you consistent chances to reinforce how you approach yourself.

When you introduce products that require a bit more attention—like aluminum and baking soda free deodorant—you interrupt the autopilot just enough to notice what you’re doing.

That moment of noticing is small, but it matters.

It turns a routine into a relationship.

Advertisement

Comfort as a Priority, Not a Bonus

In many cases, comfort is treated as optional.

If a product works, slight discomfort is tolerated. It’s seen as a trade-off, not a problem.

But what if comfort were the baseline?

Choosing products that align with your body—ones that avoid common irritants or unnecessary additives—shifts comfort from a bonus to a priority.

Advertisement

An organic face soap, for instance, often emphasizes gentler ingredients. It’s not about doing more—it’s about doing what’s necessary without excess.

This approach respects your skin’s natural state rather than overriding it.

And that respect, repeated daily, becomes part of your standard.

The Language of Consistency

Self-respect is not built on occasional actions. It’s built on consistency.

Advertisement

What you do every day matters more than what you do once in a while.

The products you use daily are part of that consistency. They are tools that either support or undermine your standards.

When you consistently choose items that align with your values—whether that’s comfort, simplicity, or awareness—you reinforce those values internally.

You’re not just making a choice once. You’re making it every day.

Advertisement

Small Decisions, Lasting Impact

It’s easy to dismiss small decisions as insignificant.

A different deodorant.
A different soap.

But these decisions are repeated hundreds, even thousands of times over the course of your life.

And repetition is what gives them weight.

Advertisement

Each time you choose something that aligns with your standards, you reinforce a pattern.

Over time, that pattern becomes part of who you are.

Not in a dramatic way, but in a steady, cumulative one.

Moving Away from Neglect

There’s a subtle form of neglect that often goes unnoticed.

Advertisement

It’s not about ignoring yourself entirely. It’s about settling.

Using products that are “fine.”
Ignoring small discomforts.
Avoiding the effort of finding something better.

This kind of neglect is easy to justify because it doesn’t feel serious.

But over time, it adds up.

Advertisement

Shifting to more intentional choices—like selecting aluminum and baking soda free deodorant or using organic face soap—is a way of moving away from that pattern.

It’s not about perfection. It’s about paying attention.

Respect Without Complexity

There’s a misconception that treating yourself well requires complexity—multiple products, elaborate routines, constant upgrades.

But self-respect doesn’t have to be complicated.

Advertisement

It can be simple.

Choosing products that align with your needs.
Paying attention to how they feel.
Making small adjustments when something isn’t right.

These are straightforward actions, but they carry meaning.

They show that you value your own experience, even in the smallest ways.

Advertisement

The Internal Shift

At first, these choices might feel external—just different products, different routines.

But over time, they create an internal shift.

You become more aware.
More selective.
More aligned with what works for you.

This shift extends beyond personal care.

Advertisement

It influences how you approach other areas of your life:
What you eat.
How you spend your time.
What you prioritize.

It all starts with small, consistent decisions.

Conclusion: The Way You Do Small Things

There’s a well-known idea that the way you do small things reflects the way you do everything.

Your daily routine is made up of small things.

Advertisement

The products you use.
The time you spend.
The attention you give.

By choosing items like aluminum and baking soda free deodorant and organic face soap, you’re not just changing what you use.

You’re changing how you approach yourself.

With more attention.
With higher standards.
With quiet, consistent respect.

Advertisement

And while these changes may seem minor, they have a way of shaping something much larger:

The relationship you have with yourself, every single day.

Continue Reading

Business

My Dividend Stock Portfolio: New February Dividend Record – 100 Holdings With 12 Buys

Published

on

My Dividend Stock Portfolio: New February Dividend Record - 100 Holdings With 12 Buys

This article was written by

I am working as a Business Analyst and Data Engineer in Germany and have started to build up a portfolio focused on Dividend Growth, both on the high and low-end yield spectrum. Primary focus is on Blue Chips with long-reaching dividend track records. I have been investing for 2 years and have been standing on the sidelines for way too long before. I love developing spreadsheets in Google and Excel to analyze financial performance and integrate these two sources with each other!Happy to connect on the various channels!

Analyst’s Disclosure: I/we have a beneficial long position in the shares of ALL STOCKS MENTIONED either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

I am not offering financial advice but only my personal opinion. Investors may take further aspects and their own due diligence into consideration before making a decision.

Advertisement

Seeking Alpha’s Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Continue Reading

Business

Shares climb on glimpse of Iran war exit ramp

Published

on

Shares climb on glimpse of Iran war exit ramp

The Australian share market has closed higher following reports US President Donald Trump is willing to wind up its military campaign against Iran without first reopening the Strait of Hormuz.

Continue Reading

Trending

Copyright © 2025